LIXT Stock Performance, Insider Transaction and News

LIXT - Lixte Biotechnology Holdings, I

Market Cap	5.96M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-4.03M	Forward P/E	-	EPS next Y	-	50D Avg Chg	-40.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-50.00%
Dividend	N/A	Price/Book	9.26	EPS next 5Y	-	52W High Chg	-88.00%
Recommedations	-	Quick Ratio	6.16	Shares Outstanding	2.25M	52W Low Chg	1.00%
Insider Own	20.48%	ROA	-87.33%	Shares Float	1.98M	Beta	-0.16
Inst Own	7.93%	ROE	-163.33%	Shares Shorted/Prior	31.16K/8.02K	Price	3.23
Gross Margin	-	Profit Margin	-	Avg. Volume	126,453	Target Price	-
Oper. Margin	-	Earnings Date	Nov 7	Volume	61,155	Change	-6.10%

Healthcare | Biotechnology | United States

About Lixte Biotechnology Holdings, I

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, I News

09/11/24	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
09/04/24	LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
08/26/24	First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
08/19/24	LIXTE Biotechnology Provides Update On Recent Activities and Developments
08/15/24	LIXTE Biotechnology Holdings to Present at Two Investor Conferences
08/14/24	Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
06/14/24	LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
06/14/24	LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
06/06/24	Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
06/03/24	LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
07:30 AM	LIXTE Biotechnology Holdings Provides Update on Recent Activities
05/08/24	LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
03/27/24	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
03/21/24	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
02/27/24	Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
02/26/24	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
01/29/24	First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
11/13/23	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
10/16/23	LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
10/09/23	LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXT Chatroom

jmpreston Posted - 17 hours ago

$LIXT headed for new lows…

N0_Brainers Posted - 2 days ago

$LIXT moving!!

StratoOTC Posted - 1 week ago

$LIXT was right about the bottom indicator. Back to previous channel. 😈

Tobymcc Posted - 1 week ago

$LIXT only 2.22k volume is crazy😭

Tobymcc Posted - 1 week ago

$LIXT might see a red day here today😬 goodluck to it tho this thing will boom one of these days and that’s fsss times just tickin till exposure

Canada_2021 Posted - 1 week ago

$LIXT got in at 1.70 holding

Smartie2000 Posted - 1 week ago

$LIXT $SRM $WHLR

N0_Brainers Posted - 1 week ago

Great Week! Septembers are messy in general. stay patient. clean your portfolio. rate cuts coming soon and market may react bearish to that imo. we will see. but hey, we f make $. $lixt is imo ready to pop. $srm another one. and we will find more. Good weekend yall! $WHLR killed it~~

N0_Brainers Posted - 1 week ago

$WHLR rule #1. take profits. #2 never yolo. #3 Don't walk with the herd $LIXT $SRM

N0_Brainers Posted - 1 week ago

$WHLR they said. open roth ira and give your money to them so they can give you 7% average and you could be millionaire and we all believe them. sick! $LIXT $SRM i guess we got different plan. let's f go!

N0_Brainers Posted - 1 week ago

$SRM NO F Brainer. $WHLR $LIXT

Tobymcc Posted - 1 week ago

$WHLR next big jumper $LIXT easy mover! Low volume! Get in early!✅✅ u will be happy to buy at current levels!

Tobymcc Posted - 1 week ago

$BLMZ $LIXT next up, easy mover!! Low volume!! Get in early!

RollingDollars Posted - 1 week ago

$LIXT

Spaggett Posted - 1 week ago

$LIXT oh so

Skyshores Posted - 2 weeks ago

$EZGO $IVP $LIXT $RVSN $SPCB

DavidScott Posted - 2 weeks ago

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $IVP $LIXT $SPCB $RVSN $EZGO

DavidScott Posted - 2 weeks ago

$EAST $IVP $LIXT $SPCB $RVSN = Well done everyone! We kept the upper hand. There was definitely some turbulence, but the bulls pulled through to close out the session nice and green. These were our team's main plays today! We are bullish and are expecting more action on these names again tomorrow. If you need any guidance, or a mentor, then feel free to message me anytime! ✅🙌

backjackreturnes1 Posted - 2 weeks ago

$LIXT could we get an update at - H.C. Wainwright 26th Annual Global Investor Conference, on demand starting at 7 a.m. EDT Bas van der Baan, CEO of LIXTE, will present an overview of the Company’s clinical trials with LB-100, its proprietary compound focused on enhancing chemotherapy and immunotherapy treatments as cancer therapies. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers, including trials funded by GSK and Roche. Look at the last updates: https://clinicaltrials.gov/study/NCT06065462 https://clinicaltrials.gov/study/NCT06012734

Tobymcc Posted - 2 weeks ago

$WHLR good plays here today sadly I didn’t trade today and won’t be tomorrow. $LIXT I got in 2 days ago MAJOR POTENTIAL, 15% up rn, and weekly chart is looking bullish as hell. Get in now before this gets pumped like a mfff

PuceslinkyTwits Posted - 2 weeks ago

$LIXT didn't buy as much as I wanted. Oh well 🤑

N0_Brainers Posted - 2 weeks ago

The plan is simple: no chasing profits. Pick a ticker, hold tight, and wait for the run. Great buy $LIXT—let’s go! $WHLR still buzzing.

N0_Brainers Posted - 2 weeks ago

launched a new series called "No Brainers" where the goal is simple: buy low, sell high. First pick? $WHLR. Next up? $LIXT. Let’s ride the wave and cash in! Let’s go!! Follow for more.

Scoty_D Posted - 2 weeks ago

$LIXT there's 2! Can we get 3!?

Spaggett Posted - 2 weeks ago

$LIXT in for a pound

backjackreturnes1 Posted - 2 weeks ago

$LIXT

N0_Brainers Posted - 2 weeks ago

$WHLR no brainer... im buying $LIXT today

N0_Brainers Posted - 2 weeks ago

$LIXT here you go. another one. buy now and wait.

DavidScott Posted - 2 weeks ago

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $FFIE $CLOV $TROO $LIXT $FUBO

Stocksrunner Posted - 2 weeks ago

Wednesday’s Resilient Stocks! These stocks hit rock bottom today but made a fierce comeback, closing higher: $MSGM, $TDUP, $ONON, $LIXT, and $WINT. 🔥 What a recovery!

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Bernards Rene	Director Director	Oct 02	Buy	2.4	10,000	24,000	25,000	10/05/23
van der Baan Bastiaan Jeroen	President and CEO President and CEO	Oct 03	Buy	2.80	10,000	28,000	11,000	10/05/23
Bernards Rene	Director Director	Dec 15	Buy	0.51	15,000	7,650	150,000	12/16/22
FORMAN ERIC	Vice President and C.. Vice President and COO	Nov 17	Buy	0.56	21,059	11,793	98,142	11/21/22
Bernards Rene	Director Director	Nov 14	Buy	0.53	52,500	27,825	125,000	11/15/22